Education

University of Delaware, Newark, Delaware, BS, 1985, Chemistry
University of North Carolina at Chapel Hill, PhD, 1990, Analytical Chemistry/ Materials Science
University of North Carolina School of Medicine, MD, 1992-1996, Medicine
University of California, San Francisco, CA Resident, 1996-00, Pathology/ Laboratory Medicine
Brigham and Womens Hospital and Harvard Medical School, Boston, MA, Clinical Fellow, 2000-01, Molecular Pathology
University of California, San Francisco, CA, Clinical Fellow, 2001-02, Surgical Pathology

Honors & Awards

  • 1984
    American Chemical Society, U. of Delaware Analytical Chemistry Award
  • 1994
    Howard Hughes Trust Fund Fellowship
  • 1994
    UNC School of Medicine Foreign Fellowship
  • 1994
    Medical Alumni Association Research Fellowship
  • 10/97-12/97
    Chief Resident, Department of Pathology, S.F. VA Medical Center
  • 4/98-6/98
    Chief Resident, Department of Pathology, S.F. General Hospital
  • 3/00-6/00
    Chief Resident, Department of Lab Medicine, S.F. General Hospital
  • 2002
    College of American Pathology Travel Award: Strategic Science Seminar Series, HER2/neu Testing of Breast Care Patients

Selected Publications

  1. Shee K, Cowan JE, Ding CC, Wang L, Pace W, Greenland N, Simko JP, Washington SL, Shinohara K, Nguyen HG, Cooperberg MR, Carroll PR. Gleason Grade Group 3 Represents a Spectrum of Disease: Results from a Large Institutional Cohort. Eur Urol Focus. 2025 May 14.  View on PubMed
  2. Roach M, Zhang J, Mohamad O, van der Wal D, Simko JP, DeVries S, Huang HC, Joun S, Schaeffer EM, Morgan TM, Keim-Malpass J, Chen E, Yamashita R, Monson JM, Naz F, Wallace J, Bahary JP, Wilke D, Batra S, Biedermann GB, Faria S, Hwang L, Sandler HM, Spratt DE, Pugh SL, Esteva A, Tran PT, Feng FY. Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials. JCO Clin Cancer Inform. 2025 May; 9:e2400284.  View on PubMed
  3. Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL. Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials. J Clin Oncol. 2025 Apr 16; JCO2400365.  View on PubMed
  4. Baxter MT, Conlin CC, Bagrodia A, Barrett T, Bartsch H, Brau A, Cooperberg M, Dale AM, Guidon A, Hahn ME, Harisinghani MG, Javier-DesLoges JF, Kamran SC, Kane CJ, Kuperman JM, Margolis DJA, Murphy PM, Nakrour N, Ohliger MA, Rakow-Penner R, Shabaik A, Simko JP, Tempany CM, Wehrli N, Woolen SA, Zou J, Seibert TM. Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer. Eur Urol Open Sci. 2025 Jan; 71:132-143.  View on PubMed
  5. Patel KR, Nguyen PL, Proudfoot JA, Liu Y, Pra AD, Spratt DE, Pollack A, Sandler HM, Efstathiou JA, Lawton C, Simko JP, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Pugh SL, Davicioni E, Tran PT, Feng FY. Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials. Eur Urol Oncol. 2024 Nov 13.  View on PubMed
  6. Tward JD, Huang HC, Esteva A, Mohamad O, van der Wal D, Simko JP, DeVries S, Zhang J, Joun S, Showalter TN, Schaeffer EM, Morgan TM, Monson JM, Wallace JA, Bahary JP, Sandler HM, Spratt DE, Rodgers JP, Feng FY, Tran PT. Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. JCO Precis Oncol. 2024 Oct; 8:e2400145.  View on PubMed
  7. Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377. Int J Radiat Oncol Biol Phys. 2024 Dec 01; 120(5):1461.  View on PubMed
  8. Starobinets O, Simko JP, Gibbons M, Kurhanewicz J, Carroll PR, Noworolski SM. The impact of benign tissue within cancerous regions in the prostate: Characterizing sparse and dense prostate cancers on whole-mount histopathology and on multiparametric MRI. Magn Reson Imaging. 2024 Dec; 114:110233.  View on PubMed
  9. Pinard A, Chen C, Van Ziffle J, Simko JP, Stohr BA, Chan E. Next-generation sequencing has diagnostic utility in challenging small/flat urothelial lesions. Ann Diagn Pathol. 2024 Dec; 73:152370.  View on PubMed
  10. Rajagopal A, Westphalen AC, Velarde N, Simko JP, Nguyen H, Hope TA, Larson PEZ, Magudia K. Mixed Supervision of Histopathology Improves Prostate Cancer Classification From MRI. IEEE Trans Med Imaging. 2024 07; 43(7):2610-2622.  View on PubMed
  11. Greenland NY, Cooperberg MR, Carroll PR, Cowan JE, Simko JP, Stohr BA, Chan E. Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification. Prostate. 2024 Aug; 84(11):1076-1085.  View on PubMed
  12. Rana Z, Kamran SC, Shetty AC, Sutera P, Song Y, Bazyar S, Solanki AA, Simko JP, Pollack A, McConkey D, Kates M, Siddiqui MM, Hiken J, Earls J, Messina D, Mouw KW, Miyamoto D, Shipley WU, Michaelson MD, Zietman A, Coen JJ, Dahl DM, Jani AB, Souhami L, Chang BK, Lee RJ, Pham H, Marshall DT, Shen X, Pugh SL, Feng FY, Efstathiou JA, Tran PT, Deek MP. Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712. Eur Urol Oncol. 2024 Oct; 7(5):986-989.  View on PubMed
  13. Ross AE, Zhang J, Huang HC, Yamashita R, Keim-Malpass J, Simko JP, DeVries S, Morgan TM, Souhami L, Dobelbower MC, McGinnis LS, Jones CU, Dess RT, Zeitzer KL, Choi K, Hartford AC, Michalski JM, Raben A, Gomella LG, Sartor AO, Rosenthal SA, Sandler HM, Spratt DE, Pugh SL, Mohamad O, Esteva A, Chen E, Schaeffer EM, Tran PT, Feng FY. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial. Eur Urol Oncol. 2024 Oct; 7(5):1024-1033.  View on PubMed
  14. Braun AE, Chan JM, Neuhaus J, Cowan JE, Kenfield SA, Van Blarigan EL, Tenggara I, Broering JM, Simko JP, Carroll PR, Cooperberg MR. The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer. Cancer. 2024 May 15; 130(10):1766-1772.  View on PubMed
  15. Liu S, Hawley SJ, Kunder CA, Hsu EC, Shen M, Westphalen L, Auman H, Newcomb LF, Lin DW, Nelson PS, Feng Z, Tretiakova MS, True LD, Vakar-Lopez F, Carroll PR, Simko J, Gleave ME, Troyer DA, McKenney JK, Brooks JD, Liss MA, Stoyanova T. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. Sci Rep. 2024 01 04; 14(1):486.  View on PubMed
  16. Greenland NY, Cowan JE, Stohr BA, Simko JP, Carroll PR, Chan E. Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer. Histopathology. 2024 Mar; 84(4):614-623.  View on PubMed
  17. Chen CV, Francois RA, Mully TW, Sangoi A, LeBoit PE, Simko JP, Chan E. Positive NKX3.1 as a diagnostic pitfall for prostate cancer in extramammary Paget's disease of genitourinary sites. Histopathology. 2024 Feb; 84(3):565-569.  View on PubMed
  18. Nguyen HG, van den Berg NS, Antaris AL, Xue L, Greenberg S, Rosenthal JW, Muchnik A, Klaassen A, Simko JP, Dutta S, Sorger JM, Munster P, Carroll PR. First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Prostatectomy. Eur Urol Oncol. 2024 Feb; 7(1):63-72.  View on PubMed
  19. Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, Cooperberg MR. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes. Eur Urol Oncol. 2024 Apr; 7(2):222-230.  View on PubMed
  20. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid. 2023 Aug; 2(8):EVIDoa2300023.  View on PubMed

Go to UCSF Profiles, powered by CTSI